Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

NCIC CTG MA.17: Increasing benefit of letrozole with longer duration of treatment as measured by the hazard ratio of disease recurrence over time

NCIC CTG MA.17: Increasing benefit of letrozole with longer duration of treatment as measured by the hazard ratio of disease recurrence over time. EJC Supplements October 2005:3(2):74, Oral presentation: 13th European Cancer Conference, Abstract Book #266, Paris, France October 31,. 2005.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.